X-linked chronic granulomatous disease (CGD) derives from defects in the CYBB gene, which encodes the gp91-phox component of NADPH oxidase. We studied the molecular basis of the disease in a kindred with variant CGD, due to a single base substitution at the sixth position of CYBB first intron. The patients' phagocytes have been shown previously to greatly increase superoxide release in response to interferon-gamma (IFN-γ) in vitro and in vivo. We examined CYBB gene expression in an Epstein-Barr virus (EBV)-transformed B-cell line from 1 patient in this kindred. These cells showed markedly decreased levels of CYBB transcripts in total RNA (5% of normal) and nuclear RNA (1.4% of normal), despite equal CYBB transcription rates in the CGD and control cells. Incubation with IFN-γ produced a 3-fold increase in CYBBtotal messenger RNA (mRNA) levels in the patient's cells, and decreased nuclear transcripts to undetectable levels. Reverse transcriptase–polymerase chain reaction analysis of RNA splicing revealed a preponderance of unspliced CYBB transcripts in the patient's nuclear RNA. In vitro incubation with IFN-γ increased by 40% the ratio of spliced relative to unspliced CYBB mRNA in nuclei from the CGD B-cell line. Total RNA harvested from the same patient's monocytes, on and off therapy with IFN-γ, showed a similar improvement in splicing. We conclude that IFN-γ partially corrects a nuclear processing defect due to the intronic mutation in theCYBB gene in this kindred, most likely by augmentation of nuclear export of normal transcripts, and improvement in the fidelity of splicing at the first intron.

Chronic granulomatous disease (CGD) is a hereditary disorder of host defense due to defective activity of a phagocyte NADPH oxidase that generates superoxide and related toxic oxygen metabolites necessary for microbial killing.1,2 Patients usually present early in life with multiple, sometimes fatal, pyogenic infections.3 

The NADPH oxidase enzyme system responsible for superoxide generation forms a small transmembrane electron transport system that results in the oxidation of NADPH on the cytoplasmic surface and the generation of superoxide on the outer surface of the membrane, which becomes the inner surface of the phagosome on invagination during phagocytosis.2,4 The terminal electron donor to oxygen is a unique, low midpoint potential flavocytochrome, termed cytochromeb558 for its absorption peak at 558 nm.5 The heterodimeric molecule combines a 91-kd glycoprotein, termed gp91-phox, for phagocyte oxidase, and a 22-kd nonglycosylated polypeptide (termed p22-phox).6,7 The CYBB gene that encodes gp91-phox was one of the first to be identified by positional cloning6 after chromosomal localization to Xp21.1; it encompasses 13 exons spanning approximately 30 kilobases (kb) of genomic DNA.8 CGD kindreds with defects in the gp91-phox component thus show X-linked inheritance and, in most cases, the cytochrome b558 is reduced or absent in their phagocytes. The rarer autosomal recessive forms9 of CGD derive from defects in genes encoding p22-phox and 2 cytosolic components of the oxidase complex: p47-phox and p67-phox.2 4 

Diverse molecular defects producing X-linked CGD have been identified within the coding region and intron boundaries of the CYBBgene; such mutations include large multigene deletions, smaller deletions and insertions, missense and nonsense substitutions, and splicing defects.9,10 Splice site mutations occur at or near the splice junction and, in most cases, result in a typical CGD phenotype with no NADPH oxidase expression.9-11 However, they can also lead to the less common and clinically less severe “variant” form of CGD, usually characterized by a uniform population of neutrophils that exhibit a low level of oxidase activity, roughly proportional to the level of cytochromeb558 expressed.9,10,12 13 

We investigated the molecular basis of the variant X-linked CGD phenotype and response to interferon gamma (IFN-γ) in a kindred with a genomic DNA mutation recently identified as a single base substitution at the sixth position of CYBB gene first intron: ATT/gtaagt→ ATT/gtaagc.9,14 This kindred has previously been shown to have phagocytes that are unusually responsive to IFN-γ, which nearly corrects the oxidase defect in vitro and in vivo.15 16 The current studies indicate that the dramatic effect of IFN-γ treatment in this kindred is largely due to posttranscriptional molecular mechanisms, including an increase of nuclear export of CYBB transcripts and improvement in the fidelity of splicing at the first intron.

Subjects

Peripheral blood samples for cell culture and monocyte preparation were obtained from the patient and from healthy volunteers. The University of Massachusetts Medical Center Committees on Protection of Human Subjects in Research approved all procedures and consent forms.

Cell preparation

Epstein-Barr virus (EBV)-transformed B lymphocytes were developed from peripheral blood mononuclear cells of healthy donors and from the patient with variant X-linked CGD. To initiate B-lymphocyte cultures, peripheral blood was fractionated by Ficoll-Hypaque centrifugation17 and the mononuclear cells were cultured with supernatants from B95-8, an EBV-producer cell line.18,19 After EBV-transformation, B lymphocytes from healthy donors or from the patient with CGD were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C in a humid atmosphere with 5% CO2. To examine the effects of cytokines, EBV-transformed B lymphocytes were cultured for 7 days with human recombinant IFN-γ (100 U/mL), tumor necrosis factor-alpha (TNF-αb 1000 U/mL), alone or in combination. These cytokines were chosen because they have well-characterized receptors and transduction mechanisms in B lymphocytes,20,21 and are strong stimulators of the NADPH oxidase system in phagocytic cell lines.22-24 In addition, the phagocytes of this CGD kindred show a dramatic response to IFN-γ both in vitro and in vivo.15 16 Cell counts and viability, monitored on a daily basis, were always above 90%.

RNA from the monocytes of the patient with CGD was generously provided by Dr R. A. B. Ezekowitz. Monocytes were isolated as adherent cells from the peripheral blood mononuclear cells of the patient with variant X-linked CGD, before and after IFN-γ therapy,25 as previously described.15 16 

Structure of RNA transcripts

The kindred's entire CYBB gene coding region and proximal 5′ flanking region has previously been shown to have a normal structure by the analysis of single strand conformation polymorphisms9 and by complementary DNA (cDNA) sequencing (R. A. B. Ezekowitz and P. E. Newburger, unpublished data). We restudied the patient's transcripts in the regions neighboring the affected intron, using polymerase chain reaction (PCR) amplification of cDNA produced by reverse transcription (RT) of total RNA, isolated by the guanidine HCl method26 from the CGD and B-cell lines. Reverse transcription was performed with SuperScript II RT (GIBCO BRL, Gaithersburg, MD) from random hexamer primers. The cDNA was amplified by a 2-stage nested PCR, with forward primers corresponding to nucleotides 3→34 (5′→3′) and 32→64 (5′→3′) and reverse primers corresponding to nucleotides 572→540 (3′→5′) and 537→503 (3′→5′) ofCYBB cDNA sequence (GenBank accession number x04011). The resultant PCR products were analyzed on agarose gels stained with ethidium bromide, extracted from gels, subcloned into pBluescript (Stratagene, La Jolla, CA), and sequenced by the ABI PRISM Dye Terminator Cycle Sequencing method (Perkin Elmer, Foster City, CA).

Gene expression studies

Northern blot analysis of total cell RNA, extracted from EBV-transformed B lymphocytes by the guanidine HCl method,26 was performed according to standard procedures.27 Hybridization probes were full-length cDNAs for the human CYBB6 and NCF128genes, encoding gp91-phox and p47-phox, respectively. The procedures for sequential cycles of filter stripping and reprobing were performed as previously described.29 Equal loading of lanes was demonstrated by the examination of gels after ethidium bromide staining and by rehybridization with a 5.8-kilobase (kb)HindIII restriction fragment of rat 18S ribosomal cDNA.30 Positive control RNA was obtained from HL-60 cells differentiated with dimethyl formamide, and negative control RNA from HeLa cells.24,31 Levels of message in CGD cells were measured quantitatively by a computer analysis of phosphorimager data and compared with normal cells. We have found that the oxidase component p47-phox is expressed in parallel with gp91-phox in EBV-transformed B cells, phagocyte cell lines, and monocyte-derived macrophages22 32; so levels of the p47-phox transcript served as a reference for comparison of the gp91-phox hybridization signals from the CGD and normal EBV-transformed B cell lines.

The transcription rates of genes encoding gp91-phox, and p47-phox were assessed by nuclear run-on assays, with minor modifications of previously published procedures.33Briefly, EBV-transformed B-lymphocyte nuclei were isolated by cell lysis in 0.05% Nonidet P-40. Freshly prepared nuclei were incubated 30 minutes at 30°C in a reaction mixture that contained [32P]UTP (9.25 MBq [250 μCi], 1.11 × 1014 Bq/mmol [3000 Ci/mmol]) in buffer modified from Greenberg et al33 by the addition of 0.8 mmol/L MnCl2. Newly synthesized RNA was prepared by guanidine extraction and ethanol precipitation.26 Equal amounts of incorporated label from each group (1-2 × 107 cpm) were then hybridized to saturating amounts of cDNA probes, immobilized on filters by slot blotting. The probes used in these experiments included cDNAs for the genes encoding gp91-phox6 and p47-phox,28 a hybridization negative control (plasmid without insert), and a constitutively expressed gene (β-actin or α-tubulin).22,32 34 We calculated relative rates of transcription by a computer analysis of phosphorimager data.

Reverse transcription–polymerase chain reaction

The cDNA from the CYBB gene encoding gp91-phox was produced by RT of total and nuclear RNA, isolated by standard procedures from the EBV-transformed patient or normal B-cell lines. Total monocyte RNA (kindly provided by Dr R. A. B. Ezekowitz) was similarly isolated from the patient's peripheral blood monocytes, both before and during therapy, with recombinant human IFN-γ, 50 μg/m2 injected subcutaneously 3 times per week.25 RT was performed with SuperScript II RT (GIBCO BRL) from random hexamer primers. The cDNA was amplified by a single-step PCR with the following primers: CYBB cDNA nucleotides 32→56 (5′→3′) and 634→600 (3′→5′); also 913→932 (5′→3′) and 1163→1144 (3′→5′); and β-actin (GenBank accession number NM001101) cDNA nucleotides 920→943 (5′→3′) and 1494→1471 (3′→5′).

For CYBB gene splicing studies, RT-PCR analysis compared the products of amplification from transcripts in which the first intron had been spliced versus those in which it had remained unspliced. The spliced transcript was amplified using primers corresponding toCYBB cDNA nucleotides 28→52 (5′→3′) (exon 1) and 407→381 (3′→5′) (exon 5). The unspliced transcript was amplified using primers corresponding to CYBB cDNA nucleotides 28→52 (5′→3′) (exon 1), and intron 1 nucleotides 226→200 (3′→5′) (CCTCCTAGGAATTCAGAAGTAAGCTAG; intron sequence kindly provided by Dr S. H. Orkin).

The semiquantitative PCR was performed by amplifying serial dilutions of cDNA preparations at successive cycle numbers to obtain conditions for linear amplification of target cDNAs. Such conditions forCYBB transcripts were generally 35 cycles (monocyte cDNA) to 40 cycles (B cell cDNA), with normal cDNA diluted 1:20 and CGD cDNA undiluted or 1:2; for β-actin transcripts, 25 cycles for all cDNAs, with no dilution necessary. PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining, and quantitated by digital photography and computer analysis with Molecular Analyst software (Bio-Rad). Levels of CYBB transcripts were adjusted for cDNA dilutions and normalized to β-actin signals from the same cDNA preparations.

Statistics

Results are represented as mean ± SD. The Wilcoxon rank sum test (Mann-Whitney U test) or the paired Student t test for matched pairs were used for comparisons between groups35; P < .05 was considered significant.

Molecular analysis of the genomic DNA of the X-linked CGD patient has previously revealed a single base substitution, ATT/gtaagt→ ATT/gtaagc,9,14 at the sixth position of first intron in the CYBB gene, which encodes the gp91-phox component of the phagocyte NADPH oxidase.6 Our first hypotheses predicted that this mutation would produce abnormal splicing with both exon skipping and normal product, as previously noted with abnormalities of intron sequences distal to the splice site, both in CYBB and other genes.9 36-41 To investigate the nature of the mutantCYBB transcripts, we amplified the cDNA of the X-linked CGD patient by RT-PCR, followed by subcloning and sequencing. No structural changes were detected in or near the first or second exons of the gp91-phox transcript of the X-linked CGD patient (results not shown).

We next examined CYBB gene expression, using patient and normal EBV-transformed B-cell lines as a model system.19 42 Figure1 shows a representative Northern blot (above) and a graphical analysis of 4 such experiments (below). These data demonstrate that IFN-γ (100 U/mL) and TNF-α (1000 U/mL) increased the expression of gp91-phox gene 1.7- to 4.5-fold in both the patient's and the normal cells (P < .05 in all situations, n = 4, Mann-Whitney U test). The cytokines also increased the expression of p47-phox gene, an unaffected component of the NADPH oxidase system, but did not reach statistical significance (P > .05 in all situations, n = 4, Mann-Whitney U test). The expression of gp91-phoxwas 6- to 13-fold higher in the normal cells compared with the patient's cells in basal conditions or after cytokine stimulation (P < .05 in all situations, n = 4, Mann-WhitneyU test). A synergistic response occurred when the patient's cells were cultured with IFN-γ and TNF-α in combination.

Fig. 1.

Northern blot of mRNA transcripts encoding gp91-phox and p47-phox.

Each lane contains 10 μg total RNA from IFN-γ–differentiated HL-60 cells, normal, and CGD B-cell lines, or HeLa cells, as indicated above. The autoradiograph shows a representative blot successively probed with32P-labeled cDNAs encoding gp91-phox, p47-phox, and (as a control for equal loading of lanes) 18S rRNA, as indicated in the left margin. The EBV-transformed B-cell lines were cultured in control conditions or in the presence of IFN-γ (100 U/mL), TNF-α (1000 U/mL), alone or in combination for 7 days, as indicated in the top margin.

Fig. 1.

Northern blot of mRNA transcripts encoding gp91-phox and p47-phox.

Each lane contains 10 μg total RNA from IFN-γ–differentiated HL-60 cells, normal, and CGD B-cell lines, or HeLa cells, as indicated above. The autoradiograph shows a representative blot successively probed with32P-labeled cDNAs encoding gp91-phox, p47-phox, and (as a control for equal loading of lanes) 18S rRNA, as indicated in the left margin. The EBV-transformed B-cell lines were cultured in control conditions or in the presence of IFN-γ (100 U/mL), TNF-α (1000 U/mL), alone or in combination for 7 days, as indicated in the top margin.

Close modal

Nuclear run-on assays (Figure 2) were performed to investigate any impairment in the transcription of the patient's CYBB gene that could account for its low expression. These experiments showed similar transcription rates of theCYBB and NCF1 genes—encoding, respectively, gp91-phox and p47-phox—in both the CGD patient's and the normal cell lines (Figure 2, P > .05 in all situations, n = 3, Mann-Whitney U test). IFN-γ (100 U/mL) and TNF-α (1000 U/mL) enhanced the transcription rates of these genes by 10% to 15% in both the CGD patient's and the normal cell lines, but the changes did not reach statistical significance (P > .05 in all situations, n = 3, Mann-Whitney U test). α-Tubulin and β-actin transcription rates were not affected by these cytokines (P > .05 in all situations, n = 3, Mann-Whitney U test).

Fig. 2.

Transcription rates of genes encoding gp91-phox, and p47-phox in CGD patient's and normal B-cell lines.

Upper panel: Representative nuclear run-on assay showing transcription rates of genes encoding gp91-phox (CYBB), and p47-phox (NCF1) in CGD and normal B cell lines. Lower panel: Graph representing compiled data from 3 experiments; columns indicate means and error bars show SDs. EBV-transformed B cells were cultured under control conditions or with IFN-γ (100 U/mL) and TNF-α (1000 U/mL) for 7 days. The negative control lanes contain pBluescript plasmid alone. Genes encoding α-tubulin and β-actin were included as transcriptionally constitutive controls.

Fig. 2.

Transcription rates of genes encoding gp91-phox, and p47-phox in CGD patient's and normal B-cell lines.

Upper panel: Representative nuclear run-on assay showing transcription rates of genes encoding gp91-phox (CYBB), and p47-phox (NCF1) in CGD and normal B cell lines. Lower panel: Graph representing compiled data from 3 experiments; columns indicate means and error bars show SDs. EBV-transformed B cells were cultured under control conditions or with IFN-γ (100 U/mL) and TNF-α (1000 U/mL) for 7 days. The negative control lanes contain pBluescript plasmid alone. Genes encoding α-tubulin and β-actin were included as transcriptionally constitutive controls.

Close modal

Using the semiquantitative RT-PCR techniques, we performed more detailed analyses of CYBB transcript abundance, distribution, and splicing. Figure 3 shows a representative image of the PCR products in an ethidium bromide-stained gel (above) and a graphical analysis of image intensity from 4 such experiments (below). The digital camera data showed markedly decreased levels of gp91-phox messenger RNA (mRNA), normalized to β-actin transcripts, in both total (5% of normal) and nuclear (1.4% of normal) RNA preparations from patient-derived cells compared with normal cells. In vitro treatment of the CGD cells with IFN-γ (Figure3) increased the level of gp91-phox transcripts 3-fold in total RNA (P < .05, n = 3, Mann-Whitney U test), while decreasing the amount of gp91-phox transcripts in the nuclear RNA preparations to undetectable levels.

Fig. 3.

RT-PCR analysis of gp91-phox transcripts in total cell and nuclear RNA preparations.

RT-PCR products of gp91-phox transcripts from the normal (Nl) or CGD patient's EBV-transformed B-cell lines, cultured with or without IFN-γ, as indicated (+IFN). Upper panel: Representative agarose electrophoresis gels, stained with ethidium bromide, of RT-PCR products from the RNA sources indicated below the image. Primers corresponded to cDNAs encoding gp91-phox or β-actin, as indicated in the left margin; size markers are indicated in the right margin. Lower panel: Graph representing compiled data from 3 experiments. Band intensity was quantitated by digital photography and computer analysis with Molecular Analyst software. Data are expressed as percentage expression relative to gp91-phox transcript levels in normal total cellular RNA, adjusted for β-actin signals; columns indicate means and error bars show SDs.

Fig. 3.

RT-PCR analysis of gp91-phox transcripts in total cell and nuclear RNA preparations.

RT-PCR products of gp91-phox transcripts from the normal (Nl) or CGD patient's EBV-transformed B-cell lines, cultured with or without IFN-γ, as indicated (+IFN). Upper panel: Representative agarose electrophoresis gels, stained with ethidium bromide, of RT-PCR products from the RNA sources indicated below the image. Primers corresponded to cDNAs encoding gp91-phox or β-actin, as indicated in the left margin; size markers are indicated in the right margin. Lower panel: Graph representing compiled data from 3 experiments. Band intensity was quantitated by digital photography and computer analysis with Molecular Analyst software. Data are expressed as percentage expression relative to gp91-phox transcript levels in normal total cellular RNA, adjusted for β-actin signals; columns indicate means and error bars show SDs.

Close modal

The RT-PCR analysis of RNA splicing used a forward primer in the first exon and alternative reverse primers in the fifth exon (to detect spiced mRNA) or the first intron (to detect unspliced mRNA), as illustrated in Figure 4. Comparison of the ratios of spliced to unspliced gp91-phox transcripts in the normal and the CGD patient-derived B-cell lines revealed slightly more unspliced than spliced transcripts in the patient's nuclear RNA (0.9 spliced/unspliced ratio), in contrast to a predominance of spliced transcripts in normal nuclear RNA (1.8 spliced/unspliced ratio), as shown in Figure 5. In vitro incubation with IFN-γ increased the amount of spliced relative to unspliced mRNA by 40% in the CGD B-cell line nuclei (P < .05, n = 4, Mann-Whitney U test).

Fig. 4.

Diagram of methodology for mRNA splicing analysis by RT-PCR.

A forward primer in the first exon and alternative reverse primers in the first intron or the fifth exon amplified products of different sizes, as indicated below the figure (bp = base pairs). The spliced transcript was amplified using a forward primer (FP) corresponding to gp91-phox cDNA exon 1 nucleotides 28→52 (5′→3′) and a reverse primer (RP) corresponding to exon 5 nucleotides 407→381 (3′→5′). The unspliced product was detected by the same forward primer, coupled with a reverse primer corresponding to intron 1 nucleotides 226→200 (3′→5′).

Fig. 4.

Diagram of methodology for mRNA splicing analysis by RT-PCR.

A forward primer in the first exon and alternative reverse primers in the first intron or the fifth exon amplified products of different sizes, as indicated below the figure (bp = base pairs). The spliced transcript was amplified using a forward primer (FP) corresponding to gp91-phox cDNA exon 1 nucleotides 28→52 (5′→3′) and a reverse primer (RP) corresponding to exon 5 nucleotides 407→381 (3′→5′). The unspliced product was detected by the same forward primer, coupled with a reverse primer corresponding to intron 1 nucleotides 226→200 (3′→5′).

Close modal
Fig. 5.

The effect of IFN-γ on splicing of nuclear CYBBtranscripts in CGD and normal B-cell lines.

RT-PCR products of CYBB nuclear mRNA amplification performed with a forward primer in the first exon and alternative reverse primers in the fifth exon or the first intron (as diagramed in Figure 4) detect, respectively, spliced (S) and unspliced (U) transcripts from nuclei prepared from normal (Nl) or CGD B-cell lines, incubated with (+IFN) or without IFN-γ. Upper panel: Representative ethidium bromide-stained agarose gel of RT-PCR products from the RNA sources indicated below the image; size markers are shown in the right margin. Lower panel: Graph representing compiled data from 3 experiments. Band intensity was quantitated by digital photography and computer analysis with Molecular Analyst software. Data are expressed as the ratio of spliced to unspliced products; columns represent means and error bars show SDs.

Fig. 5.

The effect of IFN-γ on splicing of nuclear CYBBtranscripts in CGD and normal B-cell lines.

RT-PCR products of CYBB nuclear mRNA amplification performed with a forward primer in the first exon and alternative reverse primers in the fifth exon or the first intron (as diagramed in Figure 4) detect, respectively, spliced (S) and unspliced (U) transcripts from nuclei prepared from normal (Nl) or CGD B-cell lines, incubated with (+IFN) or without IFN-γ. Upper panel: Representative ethidium bromide-stained agarose gel of RT-PCR products from the RNA sources indicated below the image; size markers are shown in the right margin. Lower panel: Graph representing compiled data from 3 experiments. Band intensity was quantitated by digital photography and computer analysis with Molecular Analyst software. Data are expressed as the ratio of spliced to unspliced products; columns represent means and error bars show SDs.

Close modal

The total RNA from peripheral blood monocytes (Figure6), harvested from the same CGD patient, on and off therapy with IFN-γ, showed a similar improvement, with a 47% increase in the ratio of spliced to unspliced message (P < .05, n = 3, paired Student t test). The nuclear RNA preparations could not be performed because of limitations on the frequency and volume of blood collections from a patient.

Fig. 6.

The effect of IFN-γ on splicing of CYBBtranscripts in total cellular RNA from the CGD patient's peripheral blood monocytes.

RT-PCR products amplified from total RNA extracted from peripheral blood monocytes harvested from the same patient on and off therapy with IFN-γ. Upper panel: Representative ethidium bromide-stained agarose gel of RT-PCR products from the RNA sources indicated below the image; size markers are shown in the right margin. Lower panel: Graph representing compiled data from 3 experiments. Labeling as in Figure5.

Fig. 6.

The effect of IFN-γ on splicing of CYBBtranscripts in total cellular RNA from the CGD patient's peripheral blood monocytes.

RT-PCR products amplified from total RNA extracted from peripheral blood monocytes harvested from the same patient on and off therapy with IFN-γ. Upper panel: Representative ethidium bromide-stained agarose gel of RT-PCR products from the RNA sources indicated below the image; size markers are shown in the right margin. Lower panel: Graph representing compiled data from 3 experiments. Labeling as in Figure5.

Close modal

The X-linked CGD derives from defects in the CYBB gene, which encodes the gp91-phox component of the NADPH oxidase.1,2 The propositus has a variant form of X-linked CGD, due to a single base substitution in the first intron ofCYBB gene.9,14 His phagocytes show a dramatic increase in superoxide release and cytochrome b levels in response to IFN-γ in vitro or in vivo.15,16 Mutations at splice junctions interfere with RNA processing and usually result in multiple splicing products, including both normal transcripts and mRNA species that are nonfunctional because of exon skipping or diminished RNA stability.9 36-41 

Our results in this CGD kindred show that the mutation, located 6 nucleotides downstream from the first splice site of the CYBBgene, did not cause any structural changes in the transcript, as demonstrated by the PCR analysis and the sequencing of the cDNA. However, the mutation caused an impairment in the CYBB gene expression, as demonstrated by the Northern blot and RT-PCR analysis. Transcription rates were equal in the nuclear run-on assays for both normal and CGD EBV-transformed B cells, indicating that the low levels of CYBB transcripts reflect instability rather than decreased synthesis. Both the nuclear and the cytoplasmic transcript levels are markedly diminished, indicating increased degradation in the nucleus; the relative preservation of CYBB transcript levels in the total RNA suggests that they are more stable once exported to the cytoplasm. The proportions of spliced and unspliced mRNA indicate a failure to process the nuclear pre-mRNA, most likely at the mutated splicing region in the first intron. Thus, the intronic mutation appears to interfere with the normal splicing process, and hence leads to low gp91-phox expression and the phenotype of variant X-linked CGD.

Most notably, in vitro incubation with IFN-γ increased the ratio of spliced relative to unspliced CYBB transcripts in nuclei from the B-cell line of the patient with CGD. A less dramatic but similar improvement in the splicing defect occurred in vivo, shown in the proportions of spliced and unspliced transcripts in the total RNA isolated from the patient's peripheral blood monocytes before and during therapy with IFN-γ. Thus, in this kindred, IFN-γ may improve cytochrome b558 levels and partially correct the CGD phenotype by increasing the rate of splicing at the CYBBfirst intron, which thus allows the nuclei to export greater quantities of the spliced mRNA to be translated into gp91-phox, the normal protein product.

These results provide a molecular basis for our previous observations of IFN-γ induction of the CYBB gene expression in this kindred.15,16,43 Previous studies of these patients with variant X-linked CGD have shown phagocyte superoxide production at 5% to 10% normal rates, with corresponding levels of cytochromeb13; they show an unusual, dramatic increase in these measures in response to IFN-γ, both in vitro and in vivo.15,16 This response derives at least in part from an enhancement on the expression of CYBB gene, as demonstrated in both previous15,16 and current experiments. In contrast, most patients with CGD show no biochemical or molecular response to IFN-γ,44 despite demonstrated clinical efficacy.25 45 

Previous studies of the current CGD kindred demonstrated larger increases in the cytochrome b558 protein levels, and still greater rises in superoxide generation and bacterial killing, compared with the magnitude of change in mRNA encoding the gp91-phox component.15,16,43 As might be expected from a multicomponent system, NADPH oxidase activity does not strictly correlate with the amount of any single component.15,16,46In addition, further posttranslational mechanisms could contribute to the activation of the NADPH oxidase system and hence, the quantitative differences between the cytochrome b558 content and the NADPH oxidase activity results.47-50 Thus, the physiological responses observed in these patients probably derives in part from the change in splicing reported here, with a major additional contribution from the functional amplification provided by the partial restoration of a missing component to an otherwise competent, or even primed, system.

The model system of EBV-transformed B lymphocytes has some limitations because of the relatively low transcriptional expression of genes encoding components of the NADPH oxidase system, compared with monocytes or phagocytic cell lines.32 Studies of cytokine-mediated gene regulation in granulocytes and monocyte-derived macrophages,23,24 human monocytic THP-1 cells,22 and human myeloid leukemia cells51have demonstrated synergistic induction of CYBB expression by IFN-γ and TNF-α that was at least in part transcriptional. Thus, unlike the EBV-transformed B-cell lines, cells in the monocytic-myeloid lineage probably up-regulate gp91-phox expression in response to IFN-γ by both transcriptional and posttranscriptional mechanisms.

Interferon-γ has previously been reported to augment expression of several other genes by increasing both transcription rates and mRNA stability. Examples include human Clara cell secretory protein production by human epithelial cells,52 synthesis of complement components in monocytes and fibroblasts,53-55expression of intercellular adhesion molecule 1 in fibroblasts56 and monocytes,57 and TNF-α generation in macrophages.58 The effect of IFN-γ onCYBB splicing has some precedent in previously reported cytokine effects on alternative splicing of transcripts encoding Trp-tRNA synthetase.59 

The effect of IFN-γ on expression of the gp91-phox gene in phagocytes from patients with X-linked CGD15 provided, in part, the basis for the clinical use of IFN-γ for prevention of infection in CGD.25 However, the large majority of patients appear to benefit clinically from other, unknown mechanisms of IFN-γ action, because most do not show a change in oxidase activity.44 The current studies demonstrate a new mechanism by which IFN-γ can up-regulate CYBB gene expression and may explain in part its unusually dramatic biochemical effect in this kindred.

We thank Drs. John Curnutte and Alan Ezekowitz for sharing data, materials, and helpful discussions; we thank Constance Whitney and Carolyn Padden for excellent technical assistance.

Supported by Brazil's Conselho Nacional de Desenvolvimento Cientı́fico e Tecnolólogico grant 200955/95-0, Fundação de Amparo à Pesquisa do Estado de São Paulo grant 96/11666-2, and State University of Campinas Medical School in house grant; by US National Institutes of Health grants DK54369 and TW00883; and by an award from the Howard Hughes Medical Institute to the University of Massachusetts Medical School under the Research Resources Program for Medical Schools.

Reprints:Peter E. Newburger, Department of Pediatrics, University of Massachusetts Medical School, 373 Plantation St, Worcester, MA 01605; e-mail: peter.newburger@umassmed.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Dinauer MC, Nauseef WM, Newburger PE. Inherited disorders of phagocyte killing. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill. In press.
2
Malech
HL
Nauseef
WM
Primary inherited defects in neutrophil function: etiology and treatment.
Semin Hematol.
34
1997
279
290
3
Thrasher
AJ
Keep
NH
Wientjes
F
Segal
AW
Chronic granulomatous disease.
Biochim Biophys Acta Mol Basis Dis.
1227
1994
1
24
4
Dinauer
MC
The phagocyte system and disorders of granulopoiesis and granulocyte function.
Hematology of Infancy and Childhood.
Nathan
DG
Orkin
ST
1998
889
920
WB Saunders
Philadelphia, PA
5
Segal
AW
Cross
AR
Garcia
RC
et al
Absence of cytochrome b245 in chronic granulomatous disease: a multicenter European evaluation of its incidence and relevance.
N Engl J Med.
308
1983
245
251
6
Royer-Pokora
B
Kunkel
LM
Monaco
AP
et al
Cloning the gene for an inherited disorder—chronic granulomatous disease—on the basis of its chromosomal location.
Nature.
322
1986
32
38
7
Parkos
CA
Dinauer
MC
Walker
LE
Allen
RA
Jesaitis
AJ
Orkin
SH
The primary structure and unique expression of the 22 kilodalton light chain of human neutrophil cytochrome b.
Proc Natl Acad Sci U S A.
85
1988
3319
3323
8
Skalnik
DG
Strauss
EC
Orkin
SH
CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter.
J Biol Chem.
266
1991
16,736
16,744
9
Rae
J
Newburger
PE
Dinauer
MC
et al
X-linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of the respiratory burst oxidase.
Am J Hum Genet.
62
1998
1320
1331
10
Roos
D
de Boer
M
Kuribayashi
F
et al
Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease.
Blood.
87
1996
1663
1681
11
De Boer
M
Bolscher
BGJM
Dinauer
MC
et al
Splice site mutations are a common cause of X-linked chronic granulomatous disease.
Blood.
80
1992
1553
1558
12
Lew
PD
Southwick
FS
Stossel
TP
Whitin
JC
Simons
ER
Cohen
HJ
A variant of chronic granulomatous disease: deficient oxidative metabolism due to a low-affinity NADPH oxidase.
N Engl J Med.
305
1981
1329
1333
13
Newburger
PE
Luscinskas
FW
Ryan
T
et al
Variant chronic granulomatous disease: modulation of the neutrophil defect by severe infection.
Blood.
68
1986
914
919
14
Condino-Neto
A
Rae
J
Padden
C
Whitney
C
Curnutte
JT
Newburger
PE
An intronic mutation in CYBB gene leading to RNA instability and variant X-linked chronic granulomatous disease [abstract].
Blood.
90
1997
599
15
Ezekowitz
RAB
Orkin
SH
Newburger
PE
Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease.
J Clin Invest.
80
1987
1009
1016
16
Ezekowitz
RAB
Dinauer
MC
Jaffe
HS
Orkin
SH
Newburger
PE
Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma.
N Engl J Med.
319
1988
146
151
17
Boyum
A
Isolation of mononuclear cells and granulocytes from human blood.
Scand J Clin Lab Invest.
21(suppl 97)
1968
1
77
18
Nilsson
K
Klein
G
Henle
W
Henle
G
The establishment of lymphoblastoid cell lines from adult and fetal human lymphoid tissue and its dependence on EBV.
Int J Cancer.
8
1971
443
450
19
Volkman
DJ
Buescher
ES
Gallin
JI
Fauci
AS
B cell lines as models for inherited phagocytic diseases: superoxide generation in chronic granulomatous disease and granules in Chediak-Higashi syndrome.
J Immunol.
133
1984
3006
3009
20
Corcione
A
Ottonello
L
Tortolina
G
et al
Recombinant tumor necrosis factor enhances the locomotion of memory and naive B lymphocytes from human tonsils through the selective engagement of the type II receptor.
Blood.
90
1997
4493
4501
21
Jouanguy
E
Lamhamedi-Cherradi
S
Altare
F
et al
Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis.
J Clin Invest.
100
1997
2658
2664
22
Condino-Neto
A
Whitney
C
Newburger
PE
Dexamethasone but not indomethacin down-regulates the human NADPH oxidase by inhibiting the expression of genes encoding components of the NADPH oxidase system.
J Immunol.
161
1998
4960
4967
23
Newburger
PE
Dai
Q
Whitney
C
In vitro regulation of human phagocyte cytochrome b heavy and light chain gene expression by bacterial lipopolysaccharide and recombinant human cytokines.
J Biol Chem.
266
1991
16,171
16,177
24
Newburger
PE
Ezekowitz
RAB
Whitney
C
Wright
J
Orkin
SH
Induction of phagocyte cytochrome b heavy chain gene expression by interferon gamma.
Proc Natl Acad Sci U S A.
85
1988
5215
5219
25
The International Chronic Granulomatous Disease Cooperative Study Group
A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease.
N Engl J Med.
324
1991
509
5160
26
Subrahmanyam
YVBK
Baskaran
N
Newburger
PE
Weissman
SM
A modified method for the display of 3′-end restriciton fragments of cDNAs: molecular profiling of gene expression in neutrophils.
Methods Enzymol.
303
1999
272
297
27
Maniatis
T
Fritsch
EF
Sambrook
J
Molecular Cloning: A Laboratory Manual.
2nd ed.
1990
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY
28
Lomax
KJ
Leto
TL
Nunoi
H
Gallin
JI
Malech
HL
Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease.
Science.
245
1989
409
412
29
Gatti
RA
Concannon
P
Salser
W
Multiple use of Southern blots.
Biotechniques.
2
1984
148
155
30
Katz
RA
Erlanger
BF
Guntaka
RV
Evidence for extensive methylation of ribosomal RNA genes in a rat XC cell line.
Biochim Biophys Acta.
739
1983
258
264
31
Newburger
PE
Speier
C
Borregaard
N
Walsh
CE
Whitin
JC
Simons
ER
Development of the superoxide-generating system during differentiation of the HL-60 promyelocytic leukemia cell line.
J Biol Chem.
259
1984
3771
3776
32
Condino-Neto
A
Newburger
PE
NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr virus transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system.
Arch Biochem Biophys.
360
1998
158
164
33
Greenberg
ME
Greene
LA
Ziff
EB
Nerve growth factor and epidermal growth factor induce rapid transient changes in proto-oncogene transcription in PC12 cells.
J Biol Chem.
260
1985
14,101
14,110
34
Krowczynska
A
Yenofsky
R
Brawerman
G
Regulation of messenger RNA stability in mouse erythroleukemia cells.
J Mol Biol.
181
1985
231
239
35
Bhattacharyya
GK
Johnson
RA
Nonparametric inference.
Statistical Concepts and Methods.
Bhattacharyya
GK
Johnson
RA
1977
505
547
John Wiley
Singapore
36
Hashinaka
K
Nishio
C
Hur
S
Sakiyama
F
Tsunasawa
S
Yamada
M
Multiple species of myeloperoxidase messenger RNAs produced by alternative splicing and differential polyadenylation.
Biochemistry.
27
1988
5906
5914
37
Kornblihtt
AR
Pesce
CG
Alonso
CR
et al
The fibronectin gene as a model for splicing and transcription studies.
FASEB J.
10
1996
248
257
38
Bayes
M
Hartung
AJ
Ezer
S
et al
The anhidrotic ectodermal dysplasia gene (EDA) undergoes alternative splicing and encodes ectodysplasin-A with deletion mutations in collagenous repeats.
Hum Mol Genet.
7
1998
1661
1669
39
Cichon
S
Anker
M
Vogt
IR
et al
Cloning, genomic organization, alternative transcripts and mutational analysis of the gene responsible for autosomal recessive universal congenital alopecia.
Hum Mol Genet.
7
1998
1671
1679
40
Kojima
T
Horiuchi
T
Nishizaka
H
et al
Genetic basis of human complement C8alpha-gamma deficiency.
J Immunol.
161
1998
3762
3766
41
Tabata
Y
Isashiki
Y
Kamimura
K
Nakao
K
Ohba
N
A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorby's fundus dystrophy with unusual clinical features.
Hum Genet.
103
1998
179
182
42
Maly
F-E
Nakamura
M
Gauchat
J-F
et al
Superoxide-dependent nitroblue tetrazolium reduction and expression of cytochrome b245 components by human tonsillar B lymphocytes and B cell lines.
J Immunol.
142
1989
1260
1267
43
Ezekowitz
RAB
Sieff
CA
Dinauer
MC
Nathan
DG
Orkin
SH
Newburger
PE
Restoration of phagocyte function by interferon-gamma in X-linked chronic granulomatous disease occurs at the level of a progenitor cell.
Blood.
76
1990
2443
2448
44
Woodman
RC
Erickson
RW
Rae
J
Jaffe
HS
Curnutte
JT
Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity.
Blood.
79
1992
1558
1562
45
Bemiller
LS
Roberts
DH
Starko
KM
Curnutte
JT
Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease.
Blood Cells Mol Dis.
21
1995
239
247
46
Yagisawa
M
You
A
Yonemaru
M
et al
Superoxide release and NADPH oxidase components in mature human phagocytes: correlation between functional capacity and amount of functional proteins.
Biochem Biophys Res Commun.
228
1996
510
516
47
Forehand
JR
Pabst
MJ
Phillips
WA
Johnston
RB
Jr
Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst: role of intracellular free calcium.
J Clin Invest.
83
1989
74
83
48
Berkow
RL
Dodson
MR
Biochemical mechanisms involved in the priming of neutrophils by tumor necrosis factor.
J Leukoc Biol.
44
1988
345
352
49
Johnston
JJ
Rintels
P
Chung
J
Sather
J
Benz
EJ
Jr
Berliner
N
Lactoferrin gene promoter: structural integrity and nonexpression in HL60 cells.
Blood.
79
1992
2998
3006
50
Woodman
RC
Curnutte
JT
Babior
BM
Evidence that de novo protein synthesis participates in a time-dependent augmentation of the chemotactic peptide-induced respiratory burst in neutrophils.
Free Radic Biol Med.
5
1988
355
361
51
Cassatella
MA
Hartman
L
Perussia
B
Trinchieri
G
Tumor necrosis factor and immune interferon synergistically induce cytochrome b245 heavy chain gene expression and nicotinamide-adenine dinucleotide phosphate oxidase in human leukemic myeloid cells.
J Clin Invest.
83
1989
1570
1579
52
Yao
XL
Ikezono
T
Cowan
M
Logun
C
Angus
CW
Shelhamer
JH
Interferon-gamma stimulates human Clara cell secretory protein production by human airway epithelial cells.
Am J Physiol.
274
1998
L864
L869
53
Mitchell
TJ
Naughton
M
Norsworthy
P
Davies
KA
Walport
MJ
Morley
BJ
IFN-gamma up-regulates expression of the complement components C3 and C4 by stabilization of mRNA.
J Immunol.
156
1996
4429
4434
54
Lappin
DF
Guc
D
Hill
A
McShane
T
Whaley
K
Effect of interferon-gamma on complement gene expression in different cell types.
Biochem J.
281
1992
437
442
55
Lappin
DF
Whaley
K
Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding-protein synthesis in human monocytes.
Biochem J.
271
1990
767
772
56
Ohh
M
Takei
F
Interferon-gamma- and phorbol myristate acetate-responsive elements involved in intercellular adhesion molecule-1 mRNA stabilization.
J Biol Chem.
269
1994
30,117
30,120
57
Ohh
M
Smith
CA
Carpenito
C
Takei
F
Regulation of intercellular adhesion molecule-1 gene expression involves multiple mRNA stabilization mechanisms: effects of interferon-gamma and phorbol myristate acetate.
Blood.
84
1994
2632
2639
58
Suk
K
Erickson
KL
Differential regulation of tumour necrosis factor-alpha mRNA degradation in macrophages by interleukin-4 and interferon-gamma.
Immunology.
87
1996
551
558
59
Tolstrup
AB
Bejder
A
Fleckner
J
Justesen
J
Transcriptional regulation of the interferon-gamma-inducible tryptophanyl-tRNA synthetase includes alternative splicing.
J Biol Chem.
270
1995
397
403
Sign in via your Institution